March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 31, 2026

Sudden Death Trajectories in HFpEF, HFmrEF

Clinical changes before death overlap across outcomes

Conexiant

March 30, 2026

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

Both groups improved, with numerically larger gains in patient-reported outcomes following a switch to tirzepatide

Conexiant

March 30, 2026

Knee OA Pain: Inulin vs Physiotherapy Effects

Prebiotic supplementation and physiotherapy show distinct and complementary effects on functional and pain sensitivity outcomes.

Conexiant

March 30, 2026

Top 10 States With the Most Favorable Tax Climate for Physicians

These 10 states differ in how they structure income, property, and sales taxes—factors that can influence overall tax exposure for physicians.

Conexiant

March 30, 2026

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Conexiant

March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant

March 27, 2026

ACSM Revises Resistance Training Guidance

Synthesized evidence clarifies which training variables enhance strength, hypertrophy, and performance.

Conexiant

March 27, 2026

Hydration Intervention Did Not Reduce Stone Recurrence

A behavioral strategy modestly increased urine volume but did not lower symptomatic events over 2 years.

Conexiant

March 26, 2026

Excess Fat Linked to Weaker Bones in Autoimmune Diabetes

Pilot study finds adiposity impairs femur strength and geometry while leaving bone mineral density unchanged, highlighting limits of standard fracture risk assessment.

Conexiant